Inozyme Pharma
-$0.02 (-0.62%) As of 5:27 PM UTC today
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inozyme Pharma and other ETFs, options, and stocks.
About INZY
Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
CEO
Axel Bolte
Employees
50
Headquarters
Boston, Massachusetts
Founded
2015
INZY Key Statistics
Market cap
159.39M
Price-Earnings ratio
—
Dividend yield
—
Average volume
121.62K
High today
$4.05
Low today
$3.85
Open price
$3.90
Volume
96.44K
52 Week high
$19.58
52 Week low
$3.54
Analyst ratings
100%
of 6 ratings
Buy
100%
Hold
0%
Sell
0%
INZY Earnings
-$1.55
-$1.03
-$0.52
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 11, Pre-Market